Drug Resistance

Drug Resistance refers to the reduced effectiveness of a therapeutic agent over time due to biological adaptations in target organisms or diseased cells, resulting in diminished clinical response. Resistance may occur through genetic mutations, pathway bypass mechanisms, efflux transporter upregulation, target downregulation, or microenvironmental factors that protect diseased cells from treatment effects. Resistance is a major challenge in oncology, infectious diseases, and certain chronic conditions requiring long-term therapy.

The pharmaceutical industry develops strategies to overcome resistance through combination regimens, next-generation inhibitors targeting resistant variants, and biomarker-guided patient selection that matches therapies to resistance profiles. Clinical development programmes monitor resistance emergence through molecular profiling, circulating tumour DNA analysis, and longitudinal biomarker tracking. Regulatory approvals often incorporate resistance-related claims, including treatment sequencing recommendations and companion diagnostics. As precision medicine advances, resistance management becomes increasingly integrated into therapeutic design, enabling more durable clinical benefit through proactive targeting of resistance pathways.